Our study suggests that sesamol is most efficient for use in cells overexpressing LAT1 (e.g., as melanoma), and with less toxicity in cells expressing low LAT1 (e.g., non-cancerous epithelial cells). The gene discussed is SLC7A5; the disease is melanoma.